ecancermedicalscience

Short Communication

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

8 Dec 2008
LR Silverman, P Fenaux, GJ Mufti, V Santini, E Hellström-Lindberg, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, D McKenzie, CL Beach

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured.

Related Articles

Gustavo Hipólito Diaz Infantes, Edgar Fermín Yan Quiroz, Luis Fernando Meza Montoya, José Richard Tenazoa Villalobos
Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem
Misbah Younus Soomro, Saqib Raza Khan, Hashim Ishfaq, Insia Ali, Mirza Rameez Samar, Arif Hameed, Nawazish Zehra, Munira Moosajee, Yasmin Abdul Rashid
Natalia Godoy-Casasbuenas, Fabian Gil, Nelson Arias, Claudia Uribe Pérez, Harold Mauricio Casas Cruz, Luisa Bravo Goyes, Esther de Vries
Sivaranjini Kannusamy, Amey Oak, Sandhya Cheulkar, Kamesh Maske, Esha Dashmukhe, Ashwini Patil, Manisha Morajkar, Manju Sengar, Ganesh Balasubramaniam, Rajesh Dikshit